Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma

Balzarotti, Monica; Santoro, Antonio; Tondini, Carlo; Fornier, M.; Bonadonna, Gianni

doi:10.1093/oxfordjournals.annonc.a010802

Cited by 18 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Studies have documented the antilymphoma activity of vinorelbine in both low grade and aggressive NHL when used in the relapsed setting. 22 Rituximab is an anti-CD20 monoclonal antibody approved for the treatment of indolent NHL, with demonstrated activity in a wide spectrum of B-cell malignancies. [23][24] Due to nonoverlapping toxicity and to possible additive or synergistic effects, rituximab is routinely used in combination with chemotherapeutic agents with encouraging results.…”

Section: Introductionmentioning

confidence: 99%

Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine

Emmanouilides

Jazirehi²,

Bonavida³

2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) responds initially to chemotherapy, however, the disease often relapses and acquires a chemoresistant phenotype. Third line treatment options such as paclitaxel, gemcitabine, and vinorelbine have been tried in patients with refractory or relapsed NHL with antilymphoma activity. Currently, rituximab (anti-CD20) has been approved for treatment of indolent NHL, with significant activity in a wide spectrum of B-cell malignancies, though a percentage of patients do not respond to rituximab treatment. Previous findings from our laboratory have demonstrated that rituximab can sensitize drug-resistant NHL B-lymphoma in vitro to some chemotherapeutic drugs. Hence, in this study, we examined the effect of combination treatment of rituximab and the drugs paclitaxel, gemcitabine, and vinorelbine on various NHL cell lines. Our findings indicate that pretreatment of NHL tumor cells with rituximab sensitizes drug-resistant NHL tumor cells to drug-mediated cytotoxicity. These findings suggest the potential clinical application of combination treatments of rituximab and paclitaxel, gemcitabine or vinorelbine in the treatment of drug/rituximab refractory non-Hodgkin's lymphoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine

Emmanouilides

Jazirehi²,

Bonavida³

2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…3 In phase I studies in humans, the doselimiting toxicity was neutropenia, with minimal nonhematologic toxicities observed. 3,4 In phase II clinical trials in humans, use of vinorelbine revealed activity against lung, 5 breast, 6 ovarian, 7 and head and neck 8 cancers in addition to non-Hodgkin's lymphoma, 9 Karposi sarcoma, 10 and mesothelioma. 11 Other toxicities that have been reported in humans are peripheral neuropathy, 12 pain at the tumor site after vinorelbine injection, 13 rare acute cardiopulmonary toxicity, 14 and skin necrosis if extravasated.…”

mentioning

confidence: 99%

Toxicity, Dosage, and Efficacy of Vinorelbine (Navelbine) in Dogs with Spontaneous Neoplasia

Poirier

Burgess

Adams

et al. 2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

The purpose of this study was to evaluate short-term adverse effects and determine a safe dosage for vinorelbine (Navelbine)-a new semisynthetic vinca alkaloid-in dogs with malignant tumors. Nineteen dogs were treated with vinorelbine as a 5-minute IV infusion every 7 days at starting dosages ranging from 10 to 20 mg/m 2. The median number of treatments per dog was 7 (range, 1-11). The maximum tolerated dosage varied between 15 and 18 mg/m 2 , and a starting dosage of 15 mg/m 2 is recommended. Neutropenia was the dose-limiting toxicity. Although efficacy was a secondary endpoint of this dosage-finding study, 2 dogs with metastatic bronchoalveolar carcinoma experienced a partial response for an overall response rate of 12.5% in 16 dogs with gross measurable disease. Three dogs with microscopic disease were treated (incompletely excised bronchoalveolar carcinoma or lymph node metastatic disease). Two died of pulmonary metastatic disease 113 and 196 days posttreatment, and 1 is still alive after at least 730 days. The well-tolerated toxicity profile and clinical activity observed in dogs with bronchoalveolar carcinoma warrants further investigation.

show abstract

“…In the patients with HD a response rate of 50 per cent was seen, compared with 44 per cent in NHL: results that are broadly in line with previous phase II single agent studies. 10,11,14 We used a less intense schedule of vinorelbine than had been used previously, and less than 5 per cent of scheduled drug administration was delayed (6 out of 132 injections) compared with the 67-80 per cent with a schedule of 30 mg/m 2 per week. The therapy was generally well-tolerated.…”

Section: Discussionmentioning

confidence: 99%

“…Responses in up to 50 per cent of patients with both relapsed refractory NHL and heavily pre-treated HD occur when vinorelbine is employed as a single agent, with some complete responses seen in both groups. 10,11 Since the majority of patients with relapsed HD and NHL will ultimately die of their disease and many are not eligible for high-dose treatments, new agents are required. We report the results of a phase II study employing single agent vinorelbine as a salvage treatment in patients with NHL and HD, half of whom had received prior high-dose therapy.…”

Section: Introductionmentioning

confidence: 99%

Vinorelbine in the treatment of lymphoma

Rule

Tighe

Davies

et al. 1998

Hematological Oncology

View full text Add to dashboard Cite

Seventeen patients with previously treated Hodgkin's disease or non-Hodgkin's lymphoma (NHL) were treated with single-agent vinorelbine (Navelbine Pierre-Fabre Medicament) in an open study to assess the activity of this new-generation vinca alkaloid. Responses were obtained in four out of eight patients with Hodgkin's disease and four out of nine patients with NHL, including four patients who had been previously treated with high-dose therapies. Toxicity was very mild. The study demonstrates worthwhile activity and justifies the inclusion of vinorelbine in combination therapies for lymphoma.

show abstract

Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma

Abstract: The good activity and tolerability of vinorelbine in relapsed intermediate-high grade lymphoma suggest its inclusion in first-line regimens, especially in elderly patients.

Cited by 18 publications

References 8 publications

Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine

Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine

Toxicity, Dosage, and Efficacy of Vinorelbine (Navelbine) in Dogs with Spontaneous Neoplasia

Vinorelbine in the treatment of lymphoma

Contact Info

Product

Resources

About